Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in japanese patients with rheumatoid arthritis

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2012, Pages 192-199

  Kato, Tomomi ^a   Hamada, Akinobu ^a,b   Mori, Shunsuke ^c   Saito, Hideyuki ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

ABCB; Methotrexate; Pharmacogenetics; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CREATININE; DNA; FOLIC ACID; METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; ADULT; AGED; ARTICLE; ATIC GENE; CELL TRANSPORT; CREATININE CLEARANCE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERYTHROCYTE LEVEL; DRUG METABOLISM; DRUG PULSE THERAPY; DRUG TRANSPORT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GGH GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MONOTHERAPY; MTHFR GENE; MTR GENE; MTRR GENE; OUTCOME ASSESSMENT; PCFT GENE; PHARMACOGENETICS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RFC1 GENE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SLCO1B1 GENE; STEADY STATE; TREATMENT DURATION;

EID: 84860266055     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-066     Document Type: Article

References (30)

1. Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins-Melton, M., Outman, R., Allison, J. J., Suarez Almazor, M., Bridges, S. L., Chatham, W. W., Hochberg, M., MacLean, C., Mikuls, T., Moreland, L. W., OöDell, J., Turkiewicz, A. M. and Furst, D. E.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum., 59: 762-784 (2008).
2. Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., Markenson, J. and Finck, B. K.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med., 343: 1586-1593 (2000).
3. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., Fox, R., Moreland, L., Olsen, N., Furst, D., Caldwell, J., Kaine, J., Sharp, J., Hurley, F. and Loew-Friedrich, I.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med., 159: 2542-2550 (1999).
4. Angelis-Stoforidis, P., Vajda, F. J. and Christophidis, N.: Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol., 17: 313-320 (1999).
5. Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M. and Kremer, J.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum., 50: 2766-2774 (2004).
6. Kumagai, K., Hiyama, K., Oyama, T., Maeda, H. and Kohno, N.: Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med., 11: 593-600 (2003).
7. Takatori, R., Takahashi, K. A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T., Hirata, T., Kawahito, Y., Satomi, Y., Nishino, H., Tanaka, T., Hirota, Y. and Kubo, T.: ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 24: 546-554 (2006).
8. Urano, W., Taniguchi, A., Yamanaka, H., Tanaka, E., Nakajima, H., Matsuda, Y., Akama, H., Kitamura, Y. and Kamatani, N.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 12: 183-190 (2002).
9. Ranganathan, P. and McLeod, H. L.: Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum., 54: 1366-1377 (2006).
10. Drozdzik, M., Rudas, T., Pawlik, A., Kurzawski, M., Czerny, B., Gornik, W. and Herczynska, M.: The effect of 3435ChT MDR1 gene polymorphism on rheumatoid arthritis treatment with diseasemodifying antirheumatic drugs. Eur. J. Clin. Pharmacol., 62: 933-937 (2006).
11. Bohanec Grabar, P., Logar, D., Lestan, B. and Dolzan, V.: Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol., 64: 1057-1068 (2008).
12. Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I. and Gawronska-Szklarz, B.: The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther., 42: 496-503 (2004).
13. Cronstein, B. N.: The mechanism of action of methotrexate. Rheum. Dis. Clin. North Am., 23: 739-755 (1997).
14. Kremer, J. M., Galivan, J., Streckfuss, A. and Kamen, B.: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum., 29: 832-835 (1986).
15. Panetta, J. C., Wall, A., Pui, C. H., Relling, M. V. and Evans, W. E.: Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin. Cancer Res., 8: 2423-2429 (2002).
16. Rhee, M. S., Lindau-Shepard, B., Chave, K. J., Galivan, J. and Ryan, T. J.: Characterization of human cellular gamma-glutamyl hydrolase. Mol. Pharmacol., 53: 1040-1046 (1998).
17. Bannwarth, B., Pehourcq, F., Schaeverbeke, T. and Dehais, J.: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet., 30: 194-210 (1996).
18. Hendel, J. and Nyfors, A.: Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur. J. Clin. Pharmacol., 27: 607-610 (1984).
19. Shen, D. D. and Azarnoff, D. L.: Clinical pharmacokinetics of methotrexate. Clin. Pharmacokinet., 3: 1-13 (1978).
20. Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S. et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31: 315-324 (1988).
21. Prevoo, M. L., van't Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van de Putte, L. B. and van Riel, P. L.: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum., 38: 44-48 (1995).
22. Dervieux, T., Orentas Lein, D., Marcelletti, J., Pischel, K., Smith, K., Walsh, M. and Richerson, R.: HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin. Chem., 49: 1632-1641 (2003).
23. Schrøder, H., Clausen, N., Ostergaard, E. and Pressler, T.: Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemother. Pharmacol., 16: 190-193 (1986).
24. Shaw, G. M., Lammer, E. J., Zhu, H., Baker, M. W., Neri, E. and Finnell, R. H.: Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am. J. Med. Genet., 108: 1-6 (2002).
25. Berkun, Y., Levartovsky, D., Rubinow, A., Orbach, H., Aamar, S., Grenader, T., Abou Atta, I., Mevorach, D., Friedman, G. and Ben-Yehuda, A.: Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis., 63: 1227-1231 (2004).
26. Hayashi, H., Fujimaki, C., Daimon, T., Tsuboi, S., Matsuyama, T. and Itoh, K.: Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J. Clin. Pharm. Ther., 34: 355-361 (2009).
27. Inoue, S., Hashiguchi, M., Takagi, K., Kawai, S. and Mochizuki, M.: Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. Yakugaku Zasshi, 129: 843-849 (2009).
28. Wessels, J. A., de Vries-Bouwstra, J. K., Heijmans, B. T., Slagboom, P. E., Goekoop-Ruiterman, Y. P., Allaart, C. F., Kerstens, P. J., van Zeben, D., Breedveld, F. C., Dijkmans, B. A., Huizinga, T. W. and Guchelaar, H. J.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum., 54: 1087-1095 (2006).
29. Wessels, J. A., van der Kooij, S. M., le Cessie, S., Kievit, W., Barerra, P., Allaart, C. F., Huizinga, T. W. and Guchelaar, H. J.: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum., 56: 1765-1775 (2007).
30. Patiño-García, A., Zalacain, M., Marrodan, L., San-Julian, M. and Sierrasesumaga, L.: Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J. Pediatr., 154: 688-693 (2009).